COCP Historical PE Ratio Notes

— Cocrystal Pharma, Inc. (COCP) is a clinical-stage biotechnology company focused on discovering & developing antiviral therapies for diseases such as influenza, COVID-19, norovirus, & hepatitis C. The company leverages its proprietary structure-based drug design technology to target viral replication enzymes, aiming to bring effective treatments to market where there is significant unmet medical need. When reviewing COCP's historical PE ratio, it's critical to understand that, as a development-stage biotech, the company typically reports minimal or negative earnings, especially prior to any FDA approval or commercial product launches. This often results in a high or undefined PE ratio during many periods, since PE is calculated as market price per share divided by earnings per share, & negative earnings can distort this metric. Investors should be aware that for pre-revenue biotechs like COCP, fluctuations in PE ratio are more reflective of investor sentiment & speculation about future potential, rather than current profitability. Thus, when examining COCP's historical charts & tables, note that periods with no or negative earnings may show very high or undefined PE ratios, which is normal for companies in this phase of development.

On this page we presented the COCP Historical PE Ratio information for Cocrystal Pharma' stock. The average COCP historical PE based on using the annualized quarterly earnings result at each measurement period (for the "E" in the PE calculation; and the closing price on earnings date as the "P") is NA. Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculation the "E" value at each measurement period, the average COCP historical PE based on this TTM earnings result method is NA. Note: any PE calculations involving negative earnings were discarded as not meaningful.

Let's now compare this COCP historical PE result, against the recent PE: when this page was posted on 8/24/2026, the most recent closing price for COCP had been 1.11, and the most recent quarterly earnings result, annualized, was NA. Meanwhile, the most recent TTM earnings summed to NA.

For self directed investors doing their due diligence on COCP or any other given stock, valuation analysis for COCP can greatly benefit from studying the past earnings and resulting PE calculations. This exercise can help inform an analysis as to whether the past earnings trajectory and current versus historical PE ratios justify the current stock value.

That's why we bring you HistoricalPERatio.com to make it easy for investors to investigate Cocrystal Pharma PE history or the past PE information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for COCP. Thanks for visiting, and the next time you need to research COCP Historical PE Ratio or the ratio for another stock, we hope you'll think of our site, as your go-to historical PE ratio research resource of choice.